RhumbLine Advisers’s MyoKardia, Inc. Common Stock MYOK Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2020
Q4 | – | Sell |
-66,022
| Closed | -$9M | – | 3058 |
|
|
2020
Q3 | $9M | Sell |
66,022
-13,671
| -17% | -$1.45M | 0.01% | 832 |
|
|
2020
Q2 | $7.7M | Buy |
79,693
+15,804
| +25% | +$1.32M | 0.01% | 915 |
|
|
2020
Q1 | $3M | Buy |
63,889
+1,710
| +3% | +$110K | 0.01% | 1328 |
|
|
2019
Q4 | $4.53M | Buy |
62,179
+2,852
| +5% | +$173K | 0.01% | 1314 |
|
|
2019
Q3 | $3.09M | Buy |
59,327
+891
| +2% | +$47.4K | 0.01% | 1473 |
|
|
2019
Q2 | $2.93M | Buy |
58,436
+13,536
| +30% | +$659K | 0.01% | 1497 |
|
|
2019
Q1 | $2.33M | Buy |
44,900
+15
| +0% | +$691 | ﹤0.01% | 1623 |
|
|
2018
Q4 | $2.19M | Buy |
44,885
+14,676
| +49% | +$808K | ﹤0.01% | 1585 |
|
|
2018
Q3 | $1.97M | Buy |
30,209
+981
| +3% | +$57.7K | ﹤0.01% | 1669 |
|
|
2018
Q2 | $1.45M | Buy |
29,228
+10,579
| +57% | +$512K | ﹤0.01% | 1845 |
|
|
2018
Q1 | $910K | Sell |
18,649
-21
| -0.1% | -$1.09K | ﹤0.01% | 1982 |
|
|
2017
Q4 | $786K | Sell |
18,670
-2,118
| -10% | -$81.6K | ﹤0.01% | 2055 |
|
|
2017
Q3 | $891K | Buy |
20,788
+2,299
| +12% | +$73.3K | ﹤0.01% | 2031 |
|
|
2017
Q2 | $242K | Buy |
18,489
+5,773
| +45% | +$76.1K | ﹤0.01% | 2659 |
|
|
2017
Q1 | $167K | Buy |
12,716
+858
| +7% | +$11K | ﹤0.01% | 2696 |
|
|
2016
Q4 | $154K | Buy |
+11,858
| New | +$183K | ﹤0.01% | 2735 |
|
RhumbLine Advisers's MYOK Position: Q4 2020 in Review
RhumbLine Advisers sold out of MyoKardia, Inc. Common Stock (MYOK) in Q4 2020, closing a stake of 66,022 shares — an estimated $9M sold.
RhumbLine Advisers first reported a position in MYOK in Q4 2016 and held it in 16 quarters. The position peaked at $9M in Q3 2020. 0 funds tracked by Wall St. Rank hold MYOK as of Q4 2020.
- RhumbLine Advisers reported no remaining MyoKardia, Inc. Common Stock position as of Q4 2020 after selling out during the quarter.
- RhumbLine Advisers sold 66,022 MyoKardia, Inc. Common Stock shares in Q4 2020, an estimated $9M.
- RhumbLine Advisers first reported a position in MyoKardia, Inc. Common Stock in Q4 2016 and held it in 16 quarters.
- RhumbLine Advisers's MyoKardia, Inc. Common Stock position peaked at $9M in Q3 2020.
- 0 funds tracked by Wall St. Rank held MyoKardia, Inc. Common Stock as of Q4 2020.
Based on RhumbLine Advisers's 13F filing for Q4 2020, filed 10 Feb 2021.